Search for: "Novartis Pharmaceuticals Corporation" Results 81 - 100 of 148
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
7 Jun 2012, 11:52 am
Consumer safety advocacy groups maintain that packages of Clear Care contact lens cleaner, a product manufactured by multinational pharmaceutical conglomerate Novartis, don’t carry a strong enough caution that the 3 percent hydrogen peroxide solution shouldn’t be used directly in the eyes, or clear enough warnings that it must be used only with the product’s proprietary case that neutralizes the solution. [read post]
29 Mar 2012, 10:00 pm by Stephanie Figueroa
Prometheus. 3) Intellectual Property Watch: Novartis India Challenge Postponed To July – This post shares how the Indian Supreme Court today postponed hearing the high-profile case involving Swiss pharmaceutical producer Novartis’ challenge of India’s patent law until July. 4) Patents Post-Grant: AIA Changes to Greatly Increase Stays of District Court Actions – This post discusses the estoppel provisions of Post Grant Review and Inter Partes Review and how they… [read post]
20 Mar 2012, 7:55 am
In support, Novartis relied upon its earlier registered CTM ZIMBUS (2 356 954) in Class 5 for ‘pharmaceutical preparations’. [read post]
12 Mar 2012, 5:41 pm by FDABlog HPM
Novartis Pharmaceuticals Corp., No. 33-av-00001 (D.N.J., Mar. 7, 2012) (Complaint) Plumbers and Pipefitters Local 572 Health and Welfare Fund v. [read post]
6 Mar 2012, 6:17 am
Earlier this year, Novartis Pharmaceuticals Corporation agreed to a $99 million settlement of a class action overtime lawsuit brought by its sales representatives. [read post]
24 Jan 2012, 6:34 pm by FDABlog HPM
District Court for the Northern District of Illinois (Eastern Division), the court denied Plaintiffs’ Seattle Children’s Hospital, Novartis Vaccines and Diagnostics, Inc., and Novartis Pharmaceuticals Corporation (collectively “Novartis”) Motion to Dismiss the lawsuit that they brought against Akorn, Inc. [read post]
9 Jan 2012, 4:00 am by Steve McConnell
Novartis Pharmaceuticals Corporation, Case No. 2:08-CV-02088 (W.D. [read post]
16 Dec 2011, 9:15 pm by Patent Docs
IBC Legal will be holding its 20th annual Biotech & Pharmaceutical Patenting conference on February 21-22, 2012 in Munich, Germany. [read post]
25 Nov 2011, 5:00 am by Bexis
Novartis Pharmaceuticals Corp., 2011 WL 5835414, slip op. [read post]
8 Sep 2011, 11:04 am by Tom Lamb
.; RECLAST (zoledronic acid) injection, Novartis Pharmaceuticals Corporation; and, the generic equivalents for these products, if any. [read post]
11 Jul 2011, 4:47 pm by FDABlog HPM
Kudos to The RPM Report team, which took note of some statements made during a recent meeting of FDA’s Arthritis Drugs Advisory Committee to discuss Novartis Pharmaceuticals Corporation’s (“Novartis’”) supplemental Biologics License Application (“sBLA”) for ILARIS (canakinumab) for the treatment of gouty arthritis attacks in certain patients.  [read post]
30 May 2011, 7:34 am by Steve McConnell
Novartis Pharmaceuticals Corp., No. 06-Civ-260 (BMC) (EDNY), and we’ve got some good news to report. [read post]
18 Apr 2011, 5:51 pm by FDABlog HPM
Prior to joining HP&M, Linda served in several pharmaceutical industry positions, including as Senior Director, Global Regulatory Policy and Intelligence, Janssen Pharmaceutical Companies of Johnson & Johnson, Executive Director, FDA Liaison, Drug Regulatory Affairs, Novartis Pharmaceuticals Corporation, and Director, Global Regulatory Affairs, Legislative Policy and Regulatory Liaison, Pharmacia Corporation.  [read post]